ACM
IMNM icon

Aster Capital Management’s Immunome IMNM Stock Holding History

Aster Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$794 Sell
118
-5,511
-98% -$123K ﹤0.01% 788
2025
Q4 		$121K Buy
+5,629
New +$98.8K 0.05% 320
2025
Q2 		– Sell
-114
Closed -$1.07K – 1293
2025
Q1 		$1.07K Sell
114
-213
-65% -$2.04K ﹤0.01% 1187
2024
Q4 		$3.47K Buy
+327
New +$3.95K ﹤0.01% 906

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Aster Capital Management's IMNM Position: Q1 2026 in Review

Aster Capital Management reduced its Immunome (IMNM) stake by 98% in Q1 2026, selling an estimated $123K and leaving 118 shares worth $794. The position accounts for ﹤0.01% of the portfolio, ranked #788.

Aster Capital Management first reported a position in IMNM in Q4 2024 and has held it in 4 quarters since. The position peaked at $121K in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Aster Capital Management held 118 shares of Immunome worth $794 as of Q1 2026.
  • Aster Capital Management sold 5,511 Immunome shares in Q1 2026, an estimated $123K.
  • Immunome made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #788 holding.
  • Aster Capital Management first reported a position in Immunome in Q4 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Immunome position peaked at $121K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.